ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate safety and efficacy of ATH-1017 in the treatment of mild
to moderate Alzheimer's disease with a randomized treatment duration of 26-weeks.